282 related articles for article (PubMed ID: 36216409)
21. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
22. Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases.
Udaondo C; Cámara C; Miguel Berenguel L; Alcobendas Rueda R; Muñoz Gómez C; Millán Longo C; Díaz-Delgado B; Falces-Romero I; Díaz Almirón M; Ochando J; Méndez-Echevarría A; Remesal Camba A; Calvo C
Pediatr Rheumatol Online J; 2022 Aug; 20(1):64. PubMed ID: 35964130
[TBL] [Abstract][Full Text] [Related]
23. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
24. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.
Schiavoni I; Olivetta E; Natalucci F; Olivieri G; Lo Presti A; Fedele G; Stefanelli P; Ceccarelli F; Conti F
Lupus; 2023 Mar; 32(3):394-400. PubMed ID: 36607313
[TBL] [Abstract][Full Text] [Related]
25. Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
Isnardi CA; Cerda OL; Landi M; Cruces L; Schneeberger EE; Montoro CC; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; de Los Ángeles Correa M; Rosemffet MG; Abarza VC; Pellet SC; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; Quintana R; de la Vega MC; Kreplak N; Pifano M; Maid P; Pons-Estel GJ; Citera G
J Rheumatol; 2022 Dec; 49(12):1385-1389. PubMed ID: 36182107
[TBL] [Abstract][Full Text] [Related]
26. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
28. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
29. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
31. Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration.
Mihaylova A; Lesichkova S; Baleva M; Nikolova-Vlahova M; Kundurzhiev T; Kolevski A; Naumova E
J Med Virol; 2023 Jan; 95(1):e28360. PubMed ID: 36448089
[TBL] [Abstract][Full Text] [Related]
32. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
34. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.
Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A
Front Immunol; 2022; 13():846248. PubMed ID: 35432314
[TBL] [Abstract][Full Text] [Related]
35. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Front Immunol; 2022; 13():896151. PubMed ID: 35844588
[TBL] [Abstract][Full Text] [Related]
36. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A; Boyton RJ; Peckham N; McKnight Á; Coates LC; Bluett J; Barber V; Cureton L; Francis A; Appelbe D; Eldridge L; Julier P; Valdes AM; Brooks T; Rombach I; Altmann DM; Nguyen-Van-Tam JS; Williams HC; Cook JA;
Lancet Respir Med; 2022 Sep; 10(9):840-850. PubMed ID: 35772416
[TBL] [Abstract][Full Text] [Related]
37. Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases.
Mrak D; Kartnig F; Sieghart D; Simader E; Radner H; Mandl P; Göschl L; Hofer P; Deimel T; Gessl I; Kain R; Winkler S; Smolen JS; Perkmann T; Haslacher H; Aletaha D; Heinz LX; Bonelli M
J Autoimmun; 2023 Feb; 135():102981. PubMed ID: 36706534
[TBL] [Abstract][Full Text] [Related]
38. Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
Giannoccaro MP; Vacchiano V; Leone M; Camilli F; Zenesini C; Panzera I; Balboni A; Tappatà M; Borghi A; Salvi F; Lugaresi A; Rinaldi R; Di Felice G; Lodi V; Lazzarotto T; Liguori R;
J Neurol; 2022 Aug; 269(8):4000-4012. PubMed ID: 35503375
[TBL] [Abstract][Full Text] [Related]
39. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G; Lippi G
Clin Chem Lab Med; 2022 May; 60(6):930-933. PubMed ID: 35303764
[TBL] [Abstract][Full Text] [Related]
40. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
